Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your ...

Raymond James analyst Michael Rose lowered the firm’s price target on United Community Banks (UCB) to $32 from $37 and keeps an Outperform ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

The Grove AI Advisory Board brings together distinguished experts in global pharmaceutical strategy, AI innovation, and regulatory compliance. Advisory members will collaborate directly with Grove ...

Corebridge Financial Inc. purchased a new position in shares of United Community Banks, Inc. (NASDAQ:UCB – Free Report) ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

UCB, a global biopharmaceutical company, today announced it will present 8 scientific abstracts, including 3 late-breaker oral presentations, highlighting key data from its innovative ...

UCB SA (OTCMKTS:UCBJF – Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 481,000 shares, a growth of 20.8% from the ...

Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.

Based in Greenville, United Community Banks (UCB) is in the Finance sector, and so far this year, shares have seen a price change of -14.27%. Currently paying a dividend of $0.24 per share ...